Answer: Brain abscess caused by Nocardia farcinica. The brain abscess grew Nocardia farcinica. The Gram stain of the organism showed long, thin, beaded, branching Gram-positive bacilli. The bacterium was partially acid fast with modified Kinyoun staining. The colonies appeared smooth and moist on sheep blood agar, in contrast to the typical dry, chalky, wrinkled colony morphology of other Nocardia species. The organism was identified as N. farcinica by matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS), with a log score of 2.173 (Biotyper RTC version 4.0.11) (Bruker Daltonics, Billerica, MA), in our laboratory, and this identification was later confirmed with secA1 gene sequencing in a reference laboratory, with a 100% match to the type strain.
N. farcinica is a common cause of nocardial brain abscesses, 45% of which present as primary abscesses (1). This organism is associated with high mortality rates, as high as 55% in immunocompromised patients despite treatment. Long-term therapy with high-dose prednisone has been shown as a risk factor for Nocardia infection (2, 3). Definitive identification of Nocardia is clinically important because antibiotic susceptibilities differ greatly within the genus, with N. farcinica being resistant to multiple antibiotics, including third- and fourth-generation cephalosporins, doxycycline, tobramycin, and clarithromycin (4).
In most clinical laboratories, Nocardia isolates are sent to a referral laboratory with molecular capabilities for 16S rRNA or secA1 gene sequencing or, more recently, multilocus sequencing analysis (MLSA) (5, 6). Although these techniques provide accurate species identification, the long turnaround time can delay treatment, resulting in poor patient outcomes (7). Recent studies have evaluated the use of MALDI-TOF MS to identify Nocardia. Currently, Nocardia species are absent in the FDA-cleared databases of Bruker and bioMérieux. It has been shown that database enhancement through library construction can overcome this limitation, especially for the low-prevalence species (6, 8, 9). Modified extraction procedures using heat or silica beads improve sensitivity (8). The use of young colonies after 18 to 48 h of growth yields better results than the use of colonies from older culture (9).
Based on the identification of N. farcinica by MALDI-TOF MS, the antibiotic regimen of our patient was changed to linezolid and trimethoprim-sulfamethoxazole. The patient remained stable until an episode of heart failure exacerbation a month later, and he ultimately passed away. The N. farcinica isolate was confirmed to be susceptible to amikacin, amoxicillin-clavulanic acid, moxifloxacin, linezolid, and trimethoprim-sulfamethoxazole, intermediate to ceftriaxone, imipenem, doxycycline, and minocycline, and resistant to ciprofloxacin, tobramycin, and clarithromycin by broth microdilution (10).
See https://doi.org/10.1128/JCM.01207-16 in this issue for photo quiz case presentation.
REFERENCES
- 1.Kumar VA, Augustine D, Panikar D, Nandakumar A, Dinesh KR, Karim S, Philip R. 2014. Nocardia farcinica brain abscess: epidemiology, pathophysiology, and literature review. Surg Infect (Larchmt) 15:640–646. doi: 10.1089/sur.2012.205. [DOI] [PubMed] [Google Scholar]
- 2.Martínez Tomás R, Menéndez Villanueva R, Reyes Calzada S, Santos Durantez M, Vallés Tarazona JM, Modesto Alapont M, Gobernado Serrano M. 2007. Pulmonary nocardiosis: Risk factors and outcomes. Respirology 12:394–400. doi: 10.1111/j.1440-1843.2007.01078.x. [DOI] [PubMed] [Google Scholar]
- 3.Peleg AY, Husain S, Qureshi ZA, Silveira FP, Sarumi M, Shutt KA, Kwak EJ, Paterson DL. 2007. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 44:1307–1314. doi: 10.1086/514340. [DOI] [PubMed] [Google Scholar]
- 4.McTaggart LR, Doucet J, Witkowska M, Richardson SE. 2015. Antimicrobial susceptibility among clinical Nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother 59:269–275. doi: 10.1128/AAC.02770-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. 2006. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 19:259–282. doi: 10.1128/CMR.19.2.259-282.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Carrasco G, de Dios Caballero J, Garrido N, Valdezate S, Canton R, Saez-Nieto JA. 2016. Shortcomings of the commercial MALDI-TOF MS database and use of MLSA as an arbiter in the identification of Nocardia species. Front Microbiol 7:542. doi: 10.3389/fmicb.2016.00542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Anagnostou T, Arvanitis M, Kourkoumpetis TK, Desalermos A, Carneiro HA, Mylonakis E. 2014. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature. Medicine (Baltimore) 93:19–32. doi: 10.1097/MD.0000000000000012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Blosser SJ, Drake SK, Andrasko JL, Henderson CM, Kamboj K, Antonara S, Mijares L, Conville P, Frank KM, Harrington SM, Balada-Llasat JM, Zelazny AM. 2016. Multicenter matrix-assisted laser desorption ionization–time of flight mass spectrometry study for identification of clinically relevant Nocardia spp. J Clin Microbiol 54:1251–1258. doi: 10.1128/JCM.02942-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Khot PD, Bird BA, Durrant RJ, Fisher MA. 2015. Identification of Nocardia species by matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol 53:3366–3369. doi: 10.1128/JCM.00780-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard—2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA. [PubMed] [Google Scholar]
